Lamichhane S, Dickens A, Buchacher T, Lou E, Charron-Lamoureux V, Kattelus R
medRxiv. 2025; .
PMID: 40061321
PMC: 11888530.
DOI: 10.1101/2025.02.18.25322275.
Dong Z, Yang S, Tang C, Li D, Kan Y, Yao L
Front Microbiol. 2025; 16:1513541.
PMID: 40012771
PMC: 11860951.
DOI: 10.3389/fmicb.2025.1513541.
Du H, Li K, Guo W, Na M, Zhang J, Na R
Animals (Basel). 2025; 15(3).
PMID: 39943163
PMC: 11815875.
DOI: 10.3390/ani15030393.
Agolino G, Cristofolini M, Vaccalluzzo A, Tagliazucchi D, Cattivelli A, Pino A
Biomolecules. 2025; 15(1).
PMID: 39858480
PMC: 11763831.
DOI: 10.3390/biom15010086.
Di Giorgio C, Urbani G, Marchiano S, Biagioli M, Bordoni M, Bellini R
Liver Int. 2025; 45(2):e16235.
PMID: 39804015
PMC: 11727439.
DOI: 10.1111/liv.16235.
TM6SF2 as new intestinal lipid player.
Tilg H, Grander C
Nat Metab. 2025; 7(1):4-5.
PMID: 39794538
DOI: 10.1038/s42255-024-01156-y.
Pharmacological Mechanisms of Bile Acids Targeting the Farnesoid X Receptor.
Qi Y, Ma Y, Duan G
Int J Mol Sci. 2025; 25(24.
PMID: 39769418
PMC: 11727972.
DOI: 10.3390/ijms252413656.
Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.
Bai S, Chandnani A, Cao S
Biomedicines. 2025; 12(12).
PMID: 39767816
PMC: 11673883.
DOI: 10.3390/biomedicines12122910.
Bile acid metabolism in type 2 diabetes mellitus.
Cadena Sandoval M, Haeusler R
Nat Rev Endocrinol. 2025; .
PMID: 39757322
DOI: 10.1038/s41574-024-01067-8.
Bile acids as a key target: traditional Chinese medicine for precision management of insulin resistance in type 2 diabetes mellitus through the gut microbiota-bile acids axis.
Wang Y, Yu J, Chen B, Jin W, Wang M, Chen X
Front Endocrinol (Lausanne). 2024; 15:1481270.
PMID: 39720247
PMC: 11666381.
DOI: 10.3389/fendo.2024.1481270.
Systematic identification of secondary bile acid production genes in global microbiome.
Yang Y, Gao W, Zhu R, Tao L, Chen W, Zhu X
mSystems. 2024; 10(1):e0081724.
PMID: 39688414
PMC: 11748489.
DOI: 10.1128/msystems.00817-24.
Microbial metabolite-receptor interactions in the gut microbiome.
Chang P
Curr Opin Chem Biol. 2024; 83:102539.
PMID: 39461049
PMC: 11588511.
DOI: 10.1016/j.cbpa.2024.102539.
Resistant Potato Starch Supplementation Reduces Serum Free Fatty Acid Levels and Influences Bile Acid Metabolism.
Bush J, Iwuamadi I, Han J, Schibli D, Goodlett D, Deehan E
Metabolites. 2024; 14(10).
PMID: 39452917
PMC: 11510092.
DOI: 10.3390/metabo14100536.
Host-microbe interaction-mediated resistance to DSS-induced inflammatory enteritis in sheep.
Yan S, Du R, Yao W, Zhang H, Xue Y, Teligun
Microbiome. 2024; 12(1):208.
PMID: 39434180
PMC: 11492479.
DOI: 10.1186/s40168-024-01932-8.
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.
Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E
Cells. 2024; 13(19.
PMID: 39404413
PMC: 11475195.
DOI: 10.3390/cells13191650.
Understanding Enterohepatic Bile Acid Pools and Their Impact on Intestinal Physiology.
Takahashi S, Gonzalez F
Cell Mol Gastroenterol Hepatol. 2024; 18(6):101400.
PMID: 39326854
PMC: 11607537.
DOI: 10.1016/j.jcmgh.2024.101400.
What defines a healthy gut microbiome?.
Van Hul M, Cani P, Petitfils C, de Vos W, Tilg H, El-Omar E
Gut. 2024; 73(11):1893-1908.
PMID: 39322314
PMC: 11503168.
DOI: 10.1136/gutjnl-2024-333378.
Strong associations between fasting lipids and glucose concentrations and ALT levels strengthened with increasing ALT quantiles.
Liu W, Shi L, Yuan M, Zhang Y, Li Y, Cheng C
Lipids Health Dis. 2024; 23(1):295.
PMID: 39267040
PMC: 11391808.
DOI: 10.1186/s12944-024-02281-z.
The Microbiome in Inflammatory Bowel Disease.
Jauregui-Amezaga A, Smet A
J Clin Med. 2024; 13(16).
PMID: 39200765
PMC: 11354561.
DOI: 10.3390/jcm13164622.
Impact of Varying Dietary Calcium Contents on the Gut Metabolomics of Yunnan Semi-Fine Wool Sheep ().
Khan M, Zhao X, Ni X, Ali S, Danzeng B, Yang H
Metabolites. 2024; 14(7).
PMID: 39057704
PMC: 11278647.
DOI: 10.3390/metabo14070381.